Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 5/20 | 0.57 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.53 |
| ▸ | FNTA | P49354 | 12/20 | 0.41 |
| ▸ | FNTB | P49356 | 12/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1551473 | 0.85 | GRIA4 (0.46) | GRIA4GRIA2FNTAFNTBKMT2A | |
| SCHEMBL3403380 | 0.84 | GRIA4 (0.45) | GRIA4GRIA2FNTAFNTBKMT2A | |
| SCHEMBL622911 | 0.80 | KDM4E (0.49) | FNTAFNTBKMT2AKDM4EALDH1A1 | |
| SCHEMBL3818516 | 0.80 | GRIA4 (0.57) | GRIA4GRIA2FNTAFNTBKMT2A | |
| SCHEMBL4412987 | 0.78 | GRIA4 (0.55) | GRIA4GRIA2FNTAFNTBKMT2A | |
| SCHEMBL3139290 | 0.77 | GRIA4 (0.37) | GRIA4GRIA2FNTAFNTBKMT2A | |
| SCHEMBL10653341 | 0.75 | GRIA4 (0.94) | GRIA4GRIA2FNTAFNTBKMT2A | |
| SCHEMBL622953 | 0.74 | L3MBTL1 (0.43) | GRIA4FNTAFNTBKMT2AALDH1A1 | |
| SCHEMBL3138044 | 0.73 | GRIA4 (0.52) | GRIA4GRIA2FNTAFNTBKMT2A | |
| SCHEMBL7815351 | 0.73 | GRIA4 (0.50) | GRIA4GRIA2FNTAFNTBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250160-B1 | THIOPHENES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS | MILLENNIUM PHARM INC (US) | 2015-11-11 | — | — | EP | disclosed |
| EP-2250160-B1 | THIOPHENES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS | MILLENNIUM PHARM INC (US) | 2015-11-11 | — | — | EP | disclosed |
| US-9029411-B2 | Thiophenes and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029411-B2 | Thiophenes and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029411-B2 | Thiophenes and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| EP-2313399-B1 | THIOPHENE OR THIAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARM INC (US) | 2014-05-28 | — | — | EP | disclosed |
| EP-2313399-B1 | THIOPHENE OR THIAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARM INC (US) | 2014-05-28 | — | — | EP | disclosed |
| US-20130217689-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217689-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217689-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| EP-2250160-A1 | THIOPHENES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| US-20100075951-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075951-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075951-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20090325925-A1 | Thiophenes and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090325925-A1 | Thiophenes and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090325925-A1 | Thiophenes and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2009154741-A1 | THIOPHENE OR THIAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009094224-A1 | THIOPHENES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009094224-A1 | THIOPHENES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075951-A1 | Heteroaryls and uses thereof | PIK3R3, AKT1S1, PIK3R1 | GRIA4 4190/4885GRIA2 2729/4885FNTA 2116/4885 |
| US-20130217689-A1 | HETEROARYLS AND USES THEREOF | PIK3R3, AKT1S1, PIK3R1 | GRIA4 4190/4885GRIA2 2729/4885FNTA 2116/4885 |
| US-20090325925-A1 | Thiophenes and uses thereof | PIK3CA, JAK2, MTOR | GRIA4 2350/4885GRIA2 2570/4885FNTA 3475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.